Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (DE:UQ1)
FRANKFURT:UQ1
uniQure (UQ1) Stock Price & Analysis
2 Followers
UQ1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.90 - €19.42
Previous Close€4.47
Volume0.00
Average Volume (3M)441.00
Market Cap
€223.65M
Enterprise Value€128.99M
Total Cash (Recent Filing)$241.36M
Total Debt (Recent Filing)$138.41M
Price to Earnings (P/E)N/A
Beta0.92
Next Earnings
Jul 31, 2024EPS Estimate
-€1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,549,437
10 Day Avg. Volume2
30 Day Avg. Volume441
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.01
Price to Sales (P/S)13.70
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.26
Enterprise Value/Gross Profit8.18
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
€15.86Price Target Upside254.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
uniQure News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAnticipation for an update on the regulatory plans following interactions with the FDA which may support a collaboration ahead of a potential registrational program.
Financial PerformanceUniQure reported higher than expected topline of $8.5M, driven by higher-than-expected collaboration revenues.
Regulatory ProgressUniQure is set to initiate FDA interactions for AMT-130, potentially clarifying the regulatory path forward.
Bears Say
Earnings ConcernNet loss per share was higher than consensus estimates.
Financial PerformanceDespite higher than expected topline, modest Hemgenix license revenues and higher cost of contract manufacturing could impact profitability.
Regulatory UncertaintyAnalyst maintains Neutral rating given the lack of clarity on AMT-130's regulatory path and potential partnership.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
31.73% Other Institutional Investors
68.27% Public Companies and
Individual Investors
UQ1 FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was €3.90 and its highest was €19.42 in the past 12 months.
What is uniQure N.V.’s market cap?
Currently, no data Available
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Jul 31, 2024 which is in 71 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 07, 2024. The company reported -€1.251 earnings per share for the quarter, missing the consensus estimate of -€1.176 by -€0.074.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -€1.13.
How many shares outstanding does uniQure N.V. have?
Currently, no data Available
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -€1.251 in its last earnings report, missing expectations of -€1.176. Following the earnings report the stock price went up 0.528%.
Which hedge fund is a major shareholder of uniQure N.V.?
Among the largest hedge funds holding uniQure N.V.’s share is Bridger Management, LLC. It holds uniQure N.V.’s shares valued at 2M.
---
uniQure Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.86 (254.68% Upside)
€15.86 (254.68% Upside)
Blogger Sentiment
Bullish
DE:UQ1 Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $339.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.63%
12-Months-Change
Fundamentals
Return on Equity
-106.11%
Trailing 12-Months
Asset Growth
22.04%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
---
UQ1 Stock 12 Month Forecast
Average Price Target
€15.86
▲(254.68% Upside)
Technical Analysis
Best Analysts Covering UQ1
1 Year
1 Year Success Rate
17/40 ratings generated profit
1 Year Average Return
+6.04%
reiterated a buy rating 11 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of +6.04% per trade.
---